$183.17 meals Payment -- Takeda Pharmaceuticals to Dr. Karen Harris

Gastroenterologist Karen Harris received a $183.17 meal payment from Takeda Pharmaceuticals for Stelara.

This page provides a detailed analysis of a $183.17 meals payment from Takeda Pharmaceuticals to Dr. Karen Harris. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$183.17
Payment Typemeals
Payment NatureFood and Beverage
Pharmaceutical CompanyTakeda Pharmaceuticals
PhysicianDr. Karen Harris
NPI Number1406570746
Physician SpecialtyGastroenterology
LocationCity, WI
Date of Payment2024-06-30
Related Drug/DeviceStelara
Conflict AssessmentLow -- Routine

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Takeda Pharmaceuticals made a $183.17 meals payment to Karen Harris, a Gastroenterology specialist in City, WI. The payment was associated with Stelara. This record details a $183.17 payment from Takeda Pharmaceuticals to Dr. Karen Harris, a Gastroenterologist. The payment was for 'Food and Beverage' categorized as a 'meal' and occurred on June 30, 2024. The payment is associated with the drug Stelara, indicating a potential relationship with its promotion.

Patient Guidance: What This Payment Means for You

This payment represents a meal provided by a pharmaceutical company and is not directly related to your medical care. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

For Gastroenterologists, meal payments are common and generally represent a small portion of total payments received from pharmaceutical companies.

Regulatory Context: Sunshine Act Requirements

Payments for meals and beverages to healthcare professionals are reportable under the Sunshine Act, provided they meet the reporting threshold.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding meals Payments

Food and beverage payments cover meals provided to physicians during pharmaceutical sales representative visits, medical conferences, and educational events. While individual meal payments tend to be small (often under $100), research published in JAMA Internal Medicine has shown that even modest meals can be associated with changes in prescribing behavior. Meal payments are the most common type of pharmaceutical payment to physicians.

Frequently Asked Questions About This Payment

What was this $183.17 payment for?

This was a meals payment of $183.17 from Takeda Pharmaceuticals to Karen Harris, categorized as "Food and Beverage". It was associated with Stelara. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Karen Harris accept pharmaceutical money?

Yes, Karen Harris received this $183.17 payment from Takeda Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Karen Harris's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this meals payment?

A meals payment of $183.17 is generally routine and common in the industry. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Gastroenterology?

To compare this payment against Gastroenterology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Gastroenterology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Karen Harris's relationship with Takeda Pharmaceuticals?

The payment amount is relatively small, suggesting it was for a meal rather than a significant educational event. This $183.17 meals payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Gastroenterology?

The payment was made by Takeda Pharmaceuticals, a known pharmaceutical company.

What should patients do after learning about this payment?

This payment represents a meal provided by a pharmaceutical company and is not directly related to your medical care.

What else should I know about this meals payment?

The specific drug mentioned is Stelara, which is used to treat gastrointestinal conditions.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.